Livzon Pharmaceutical Group Secures Drug Registration Certificate for Key Infertility Treatment
Key Points for Investors
- Regulatory Milestone: Livzon MABPharm Inc., a controlling subsidiary of Livzon Pharmaceutical Group Inc., has received the Drug Registration Certificate for Recombinant Human Follitropin Alfa Solution for Injection from the National Medical Products Administration (NMPA) of China. This is an important regulatory approval for the company’s biologics portfolio.
- Product Details: The approved product, under the trade name 麗優寶, is a biosimilar for Follitropin Alfa, a critical hormone used in fertility treatments. It’s supplied as a pre-filled pen (33 μg / 450 IU per 0.75 mL) with a shelf life of 24 months. The approval allows Livzon to manufacture and market the drug domestically until at least May 2031.
- Indications and Market Potential: The drug is indicated for:
- Treatment of anovulation (including PCOS) in women who are unresponsive to clomiphene citrate
- Ovarian stimulation in assisted reproductive technologies (ART) such as IVF, GIFT, and ZIFT
- Treatment of patients with severe LH and FSH deficiency (serum LH <1.2 IU/L)
- Clinical Performance: The biosimilar has completed Phase I-III clinical trials, demonstrating equivalence to originator drugs in efficacy, safety, immunogenicity, and pharmacokinetics. The injection pen design enhances patient convenience and compliance.
- R&D Investment: Livzon has invested approximately RMB121.69 million in the development of this product, reflecting a significant commitment to the fertility treatment market.
Market Landscape and Competitive Position
- As of the latest data, there are only eight approved versions (four imported and four domestic) of Recombinant Human Follitropin Alfa Solution for Injection in China. This limited competition is notable given the rapidly growing market.
- With rising rates of infertility and a younger demographic affected, the demand for fertility treatments is increasing. According to IQVIA, the domestic terminal sales value for FSH drugs reached approximately RMB2.541 billion in 2025, with Recombinant Human Follitropin Alfa accounting for over 56% of this market. From January to March 2026 alone, sales were RMB0.538 billion, underscoring robust and ongoing demand.
Shareholder Considerations and Price-Sensitive Information
- Potential Impact on Share Price: This regulatory approval is a significant milestone that could positively influence Livzon’s future revenues and market competitiveness in the fertility treatment sector. The company now has the green light to manufacture and distribute this biosimilar, which addresses a major and growing therapeutic need in China.
- Risk Factors: The company notes that the product’s commercial performance will depend on market conditions and other uncertainties. Investors should be aware of the potential volatility and risk inherent in the sector.
Corporate Information
- The approval is valid until 26 May 2031, and the product will be manufactured by Livzon Group Livzon Pharmaceutical Factory.
- The executive leadership includes President Mr. Liu Daping and Vice Chairman Mr. Tang Yanggang, with a diverse board representing executive, non-executive, employee, and independent directors.
Conclusion
Livzon Pharmaceutical Group’s successful registration of its Recombinant Human Follitropin Alfa Solution for Injection marks a strategic win in the high-growth fertility treatment market. This development is both newsworthy and potentially price-moving, given the company’s strengthened competitive position and the substantial market demand.
Disclaimer: The above article is for informational purposes only and does not constitute investment advice. Investors should consider all relevant factors and consult with professional advisors before making any investment decisions. The operating environment and actual commercial performance of the product are subject to market risks and uncertainties.
珠海麗珠醫藥集團獲批重組人生長激素 α 注射液新藥證書 — 投資者重點詳盡報導（粵語版）
投資者重點摘要
- 監管重大進展： 珠海麗珠單抗生物技術有限公司（Livzon MAB），為麗珠醫藥集團控股子公司，獲得國家藥品監督管理局（NMPA）核准的重組人生長激素 α 注射液（Follitropin Alfa，商品名：麗優寶）藥品註冊證書，對公司生物藥組合發展極具戰略意義。
- 產品詳情： 此產品為 Follitropin Alfa 生物類似藥，主要用於不孕症治療，規格為預充式注射筆（33微克/450 IU/0.75毫升），有效期24個月，批准生產與銷售至2031年5月。
- 適應症及市場潛力： 主要用於：
- 治療對克羅米芬無反應的女性排卵障礙（包括多囊卵巢綜合症PCOS）
- 輔助生殖技術（IVF、GIFT、ZIFT）中的卵巢過度刺激
- 治療嚴重LH/FSH缺乏症（血清LH <1.2 IU/L）
- 臨床表現： 已完成I-III期臨床試驗，證明與原研藥療效、安全、免疫原性及藥代動力學等效，注射筆設計提升患者依從性。
- 研發投入： 研發總投入約1.22億元人民幣，顯示公司對生殖領域市場的高度重視。
市場格局與競爭優勢
- 目前中國僅有8款重組人生長激素 α 注射液獲批（4款進口、4款國產），競爭有限。
- 不孕症發病率逐年上升，患者年輕化明顯。據IQVIA數據，2025年FSH藥物國內終端銷售額約25.41億元人民幣，重組Follitropin Alfa佔比超過56%。2026年首季銷售額已達5.38億元，市場需求強勁。
股東須知及可能影響股價信息
- 潛在股價影響： 此次新藥獲批有望顯著提升公司在生殖治療市場的收入及競爭力，具備刺激股價的潛力。
- 風險提示： 產品最終業績仍受市場環境等不確定因素影響，投資者需審慎評估。
公司資料
- 批准有效期至2031年5月26日，生產由麗珠集團麗珠製藥廠負責。
- 管理層包括總裁劉大平、副董事長唐陽剛等，董事會組成多元。
總結
麗珠醫藥集團重組人生長激素 α 注射液註冊成功，抓住生殖醫藥高增長市場，對業務發展具備戰略意義，消息具備市場關注及潛在股價推動力。
免責聲明： 以上內容僅供參考，不構成任何投資建議。投資者應綜合考慮所有相關因素，並諮詢專業人士後作出投資決策。產品實際業績及市場表現受多種風險及不確定性因素影響。
